Clinical bottom line
Type 2 innate lymphoid cells (ILC2s) are increasingly recognized as key players in eosinophilic autoimmune diseases, contributing to tissue inflammation and remodeling. Emerging therapies targeting ILC2s represent a novel immunomodulatory approach with potential to improve outcomes in conditions characterized by eosinophilic inflammation. Current evidence is preliminary but suggests that modulating ILC2 activity could reduce disease severity and limit tissue damage. However, clinical data on efficacy and safety remain limited, and further validation in well-designed trials is needed before these therapies can be integrated into routine practice.
What the evidence shows
ILC2s are innate immune cells that produce type 2 cytokines such as IL-5 and IL-13, driving eosinophilic inflammation implicated in several autoimmune diseases with eosinophilic features (Kumar Vijay et al., 2022). These cells contribute to tissue fibrosis and chronic inflammation, making them attractive therapeutic targets. Recent reviews highlight the potential of ILC2-targeted therapies to modulate immune responses without broadly suppressing adaptive immunity, which may reduce infection risk compared to conventional immunosuppressants (Barnie Prince Amoah et al., 2022; Clottu Aurelie S. et al., 2022).
Biomarker studies in eosinophilic airway diseases, such as asthma, demonstrate that ILC2 levels correlate with disease activity and eosinophilic inflammation, supporting their pathogenic role and utility as therapeutic targets (Dong Liang et al., 2016). Although asthma is not an autoimmune disease per se, these findings provide a mechanistic rationale for targeting ILC2s in eosinophilic autoimmune conditions.
Therapeutic strategies under investigation include monoclonal antibodies against ILC2-activating cytokines (e.g., IL-33, TSLP), small molecules modulating ILC2 function, and approaches to deplete or inhibit ILC2s directly (Barnie Prince Amoah et al., 2022). Preclinical models show that blocking ILC2 pathways reduces eosinophilic infiltration and tissue damage, but human clinical trial data remain sparse.
Safety considerations are informed by experience with biologics targeting related pathways. While B-cell targeted therapies have well-characterized safety profiles, the safety of ILC2-specific interventions is less established and warrants careful monitoring for off-target effects and immune dysregulation (Bruce Ian N. et al., 2013; Chatenoud Lucienne et al., 2006).
Caveats and uncertainty
The clinical evidence for ILC2-targeted therapies in eosinophilic autoimmune diseases is largely hypothesis-generating and derived from preclinical studies or extrapolated from related conditions such as asthma. There is a paucity of randomized controlled trials directly assessing efficacy and safety in autoimmune populations.
ILC2 biology is complex and context-dependent; these cells also participate in tissue repair and homeostasis, raising concerns about potential adverse effects of their inhibition. Additionally, patient heterogeneity and disease complexity may influence therapeutic responses, necessitating biomarker-driven patient selection.
Long-term safety data are lacking, and the risk of unintended immunosuppression or exacerbation of other immune pathways remains uncertain. The balance between efficacy and safety must be carefully evaluated in future clinical studies.
How this may change practice
If validated, therapies targeting ILC2s could offer a novel mechanism-based treatment option for eosinophilic autoimmune diseases refractory to current immunosuppressive regimens. These therapies might provide more selective modulation of pathogenic inflammation with potentially fewer systemic side effects.
Clinicians should remain aware of ongoing clinical trials and emerging data to identify patients who may benefit from such interventions in the future. Integration of ILC2 biomarkers into clinical practice could facilitate personalized treatment approaches.
Currently, ILC2-targeted therapies remain investigational. Their use should be confined to clinical trial settings until robust efficacy and safety data are available.